CDK6 and acute myeloid leukemia: Inhibition of FLT3-ITD in AML leads to down regulation of cyclin D2 and D3, both activators of CDK6 (Wang et al., 2007), which suggests that CDK6 may be an additional candidate for therapeutic targeting in FLT3-ITD-driven AML.